Korro Bio Boosts Executive Pay and Severance in New Agreement

Reuters

2025/12/19

<a href="https://laohu8.com/S/KRRO">Korro Bio</a> Boosts Executive Pay and Severance in New Agreement

Korro Bio Inc. has entered into an amended and restated employment agreement with Jeffrey Cerio, effective December 15, 2025. The new agreement increases Dr. Cerio's annual base salary to $425,000 and enhances severance terms, providing nine months of salary in the event of termination without cause or resignation for good reason, and 12 months of salary in similar circumstances within the change in control period. Dr. Cerio has also been awarded a $100,000 cash bonus, payable in two installments—half on December 31, 2025, and half on or about June 30, 2026—contingent on continued service. Additionally, he has been granted 41,902 restricted stock units, vesting in two equal tranches on June 15, 2026, and December 15, 2026, subject to continued service.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-324795), on December 18, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2592918197"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592918197\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592918197?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 05:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592918197","market":"fut","top_or_hot":-1,"title":"Korro Bio Boosts Executive Pay and Severance in New Agreement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a> Boosts Executive Pay and Severance in New Agreement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Korro Bio Inc. has entered into an amended and restated employment agreement with Jeffrey Cerio, effective December 15, 2025. The new agreement increases Dr. Cerio's annual base salary to $425,000 and enhances severance terms, providing nine months of salary in the event of termination without cause or resignation for good reason, and 12 months of salary in similar circumstances within the change in control period. Dr. Cerio has also been awarded a $100,000 cash bonus, payable in two installments—half on December 31, 2025, and half on or about June 30, 2026—contingent on continued service. Additionally, he has been granted 41,902 restricted stock units, vesting in two equal tranches on June 15, 2026, and December 15, 2026, subject to continued service.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-324795), on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Korro Bio Boosts Executive Pay and Severance in New Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKorro Bio Boosts Executive Pay and Severance in New Agreement\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-19 05:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a> Boosts Executive Pay and Severance in New Agreement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Korro Bio Inc. has entered into an amended and restated employment agreement with Jeffrey Cerio, effective December 15, 2025. The new agreement increases Dr. Cerio's annual base salary to $425,000 and enhances severance terms, providing nine months of salary in the event of termination without cause or resignation for good reason, and 12 months of salary in similar circumstances within the change in control period. Dr. Cerio has also been awarded a $100,000 cash bonus, payable in two installments—half on December 31, 2025, and half on or about June 30, 2026—contingent on continued service. Additionally, he has been granted 41,902 restricted stock units, vesting in two equal tranches on June 15, 2026, and December 15, 2026, subject to continued service.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-324795), on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRRO","symbol_name":"Korro Bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL5LdXHy:1","article_id":"2592918197","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592918197","pubTimestamp":1766091973,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Korro Bio Inc. has entered into an amended and restated employment agreement with Jeffrey Cerio, effective December 15, 2025. The new agreement increases Dr. Cerio's annual base salary to $425,000 and enhances severance terms, providing nine months of salary in the event of termination without cause or resignation for good reason, and 12 months of salary in similar circumstances within the change in control period. Dr. Cerio has also been awarded a $100,000 cash bonus, payable in two installments—half on December 31, 2025, and half on or about June 30, 2026—contingent on continued service. Additionally, he has been granted 41,902 restricted stock units, vesting in two equal tranches on June 15, 2026, and December 15, 2026, subject to continued service.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRRO":"Korro Bio, Inc.","BK4139":"生物科技"},"translate_title":"Korro Bio在新协议中提高高管薪酬和遣散费","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRRO":0.9},"content_text":"Korro Bio Boosts Executive Pay and Severance in New Agreement\n    \n\n        Korro Bio Inc. has entered into an amended and restated employment agreement with Jeffrey Cerio, effective December 15, 2025. The new agreement increases Dr. Cerio's annual base salary to $425,000 and enhances severance terms, providing nine months of salary in the event of termination without cause or resignation for good reason, and 12 months of salary in similar circumstances within the change in control period. Dr. Cerio has also been awarded a $100,000 cash bonus, payable in two installments—half on December 31, 2025, and half on or about June 30, 2026—contingent on continued service. Additionally, he has been granted 41,902 restricted stock units, vesting in two equal tranches on June 15, 2026, and December 15, 2026, subject to continued service.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-324795), on December 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}